Remove Bioavailability Remove Clinical Development Remove In-Vitro Remove Licensing
article thumbnail

Betta to commercialise C4 Therapeutics’ CFT8919 in greater China

Pharmaceutical Technology

C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China region. It is expected to accelerate the development of CFT8919 in important international markets.